Leucid Bio Chief Scientific Officer John Maher publishes new research on pCAR technology

  • New data highlight the strength and versatility of Leucid’s proprietary, next-generation technology
  • pCAR has now achieved proof-of-concept across a range of co-stimulatory domains, binders, targets and target combinations in pre-clinical liquid and solid tumour cell lines/models
  • John Maher has been an early pioneer of CAR T-cell immunotherapy with a focus on solid tumours

London, UK – 16 March 2022 – Leucid Bio (“Leucid” or the “Company”), a biotech company pioneering next-generation cell therapies for hard-to-treat cancers, today notes the publication of two studies in Cell Reports Medicine  and Frontiers in Immunology co-authored by its Chief Scientific Officer John Maher.

Read more